| 摘要 |
<p>The present invention relates to compounds that inhibit the binding of glycosaminoglycans and proteoglycans to beta amyloid peptide (A(beta); Aβ), and to compounds that inhibit Aβ activation of complement. In one aspect, the compound is a peptide having an amino acid sequence X-X-N-X, in which X is an amino acid with a cationic side chain and N is a neutral amino acid. In another aspect, the compound is a peptide having an amino acid sequence X-X-N-X-Z, in which X is an amino acid with a cationic side chain, N is a neutral amino acid and Z is a neutral amino acid. In yet another aspect, the compound is peptide having an amino acid sequence X1-N-X2-X3, in which at least two of X1, X2, and X3 are independently an amino acid with an anionic side chain and the third X is an amino acid with an anionic side chain or a neutral amino acid and N is independently a neutral amino acid. In yet a further aspect, the compound is an anionic disaccharide. The invention also relates to a method for treating Alzheimer's disease comprising administering a therapeutically effective amount of a compound as described above to a subject suffering from Alzheimer's disease. Pharmaceutical compositions are also provided.</p> |
